دورية أكاديمية
Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
| العنوان: | Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. |
|---|---|
| المؤلفون: | Fouquet G; Hematology Department, Huriez Regional University Hospital, Lille, France., Tardy S, Demarquette H, Bonnet S, Gay J, Debarri H, Herbaux C, Guidez S, Michel J, Perrot A, Serrier C, Miljkovic D, Avet Loiseau H, Facon T, Hulin C, Leleu X |
| المصدر: | Cancer [Cancer] 2013 Oct 15; Vol. 119 (20), pp. 3680-6. Date of Electronic Publication: 2013 Aug 06. |
| نوع المنشور: | Journal Article; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005- >: Hoboken, NJ : Wiley Original Publication: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.] |
| مواضيع طبية MeSH: | Drug Resistance, Neoplasm* , Salvage Therapy*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Multiple Myeloma/*drug therapy , Neoplasm Recurrence, Local/*drug therapy, Adult ; Aged ; Dexamethasone/administration & dosage ; Disease Progression ; Female ; Follow-Up Studies ; Humans ; Lenalidomide ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Survival Rate ; Thalidomide/administration & dosage ; Thalidomide/analogs & derivatives |
| مستخلص: | Background: Lenalidomide in combination with dexamethasone (Len/Dex) is indicated for patients with recurrent/refractory multiple myeloma (RRMM) who were treated with 1 prior therapy until evidence of disease progression. The objective of the current study was to determine the efficacy and safety profile of long-term exposure to Len/Dex. Methods: A total of 50 patients with RRMM who were treated with long-term Len for ≥ 2 years from 2 Intergroupe Francophone du Myélome (IFM) centers (Lille and Nancy) were included in the current study. Results: The median age of the patients was 58 years, with 30% of the patients aged >65 years, 49% having an International Staging System stage of 2 and 3, 12% having severe renal insufficiency, and 8% demonstrating an adverse result on fluorescence in situ hybridization. Approximately 56% of the patients received treatment with Len/Dex for ≥ 3 years. The median duration of treatment with Len/Dex was 3 years (range, 2 years-7 years). The response rates for partial response or better and very good partial response or better for the overall cohort were 96% and 74%, respectively, which is similar to patients exposed to Len for ≥ 3 years. With a median follow-up of 4 years, 19 (38%) patients had stopped treatment with Len/Dex. The time to disease progression rate at 37 months was 78% and 91%, respectively, in patients exposed to Len for 2 years to <3 years and for ≥ 3 years (P=025). The safety profile was manageable, similar to that of Len when administered for a shorter period of time; 16% of patients had grade 3 to 4 neutropenia, 6% had thrombopenia, 6% had anemia, and 20% experienced thromboembolic events, all of venous type. The annual incidence rate of second primary malignancy was 1.96% in the current series. Conclusions: The results of the current study confirmed that the Len/Dex combination is feasible for long-term use in patients with RRMM, with a significant benefit noted in terms of time to disease progression for prolonged treatment with Len/Dex. (Copyright © 2013 American Cancer Society.) |
| فهرسة مساهمة: | Keywords: lenalidomide; long-term efficacy; long-term toxicity; multiple myeloma; prolonged progression-free survival |
| المشرفين على المادة: | 4Z8R6ORS6L (Thalidomide) 7S5I7G3JQL (Dexamethasone) F0P408N6V4 (Lenalidomide) |
| تواريخ الأحداث: | Date Created: 20130808 Date Completed: 20131203 Latest Revision: 20181202 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1002/cncr.28274 |
| PMID: | 23921945 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.28274 |